Biotech Values

[daved]

The gist of my previous posts was that the LEO deal was proving to be very costly to GTCB. To portray this morning's cash guidance as anything but LEO related cash burn guidance is obfuscation.

This morning's burn forecast relieved my concern that they had an ongoing desire to hide anything. The 10Q's (for anyone who delved into them) showed the trend adequately.

I never thought GTCB had changed any terms much less said it. I thought their 10K ambiguous or misguided with regard to the burden for clinical production costs.

"In our collaboration with LEO we will continue to be responsible for the production of ATryn. LEO will pay for all product used in clinical studies as well as for commercial sale. For product that sold for approved therapeutic use, LEO will pay us a royalty on all commercial sales, as well as a transfer price that we believe will provide us a margin on our cost of production. LEO will pay us at cost for all product used in clinical studies and will be responsible for all other clinical study costs for approval in Europe.


Good job trying to change the expense concerns I voiced as a devious basher plot.

Regards,

Dave